Rani Therapeutics Holdings, Inc. (RANI) News
Filter RANI News Items
RANI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RANI News Highlights
- RANI's 30 day story count now stands at 2.
- Over the past 7 days, the trend for RANI's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- BODY, DE and DEC are the most mentioned tickers in articles about RANI.
Latest RANI News From Around the Web
Below are the latest news stories about RANI THERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate RANI as an investment opportunity.
Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin TriagonistPeak Decreases in Body Weights All data are means ± SE - Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study – - Preclinical data support the potential for the RaniPill platform to enable oral delivery of multiple obesity treatments - SAN JOSE, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral de |
What Makes Rani Therapeutics Holdings, Inc. (RANI) a New Buy StockRani Therapeutics Holdings, Inc. (RANI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Jean-Luc Butel Buys Handful Of Shares In Rani Therapeutics HoldingsPotential Rani Therapeutics Holdings, Inc. ( NASDAQ:RANI ) shareholders may wish to note that the Independent Director... |
Pleasing Signs As A Number Of Insiders Buy Rani Therapeutics Holdings StockWhen a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase... |
Rani Therapeutics Holdings Inc (RANI) Reports Q3 2023 Financial Results and Corporate DevelopmentsStrategic Focus and Extended Cash Runway Highlighted |
Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate UpdateAdalimumab 11mg via RaniPill HC vs Adalimumab Biosimilar 5mg via Subcutaneous Injection Adalimumab 11mg via RaniPill HC vs Adalimumab Biosimilar 5mg via Subcutaneous Injection Pharmacokinetics of Interleukin (16.5mg) Delivered Orally via RaniPill HC Capsules to Awake Canines (N=6) Pharmacokinetics of Interleukin (16.5mg) Delivered Orally via RaniPill HC Capsules to Awake Canines (N=6) - Cash runway extended into 2025 - - Announced strategic program prioritization, expansion of manufacturing and |
Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill® Technology Platform; Reports Preliminary Third Quarter 2023 Financial Results- Cash runway extended into 2025 - - Cash runway expected to extend beyond topline results from Phase 2 trial for RT-102, topline results from Phase 1 trial for RT-111, and development of RaniPill® HC to be Phase 1 ready - - Expansion of manufacturing footprint is expected to enable increased scale and support capacity for potential partner programs - - RT-101 program discontinued; RT-105 and RT-110 programs paused - - The company will reduce its workforce by approximately 25% - SAN JOSE, Calif. |
The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study– Daily administration for 60 days was well-tolerated with no treatment-related adverse events – – Preclinical data support the safety and tolerability of RaniPill® capsule for subsequent clinical studies – SAN JOSE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced preclinical data supporting the safety and tolerab |
Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study- RaniPill® HC achieved 4/4 successful drug delivery of orally administered Humira® (adalimumab) - - RaniPill® HC has achieved a cumulative >90% success rate across multiple preclinical studies – - RaniPill® HC shortlisted as a finalist by Fierce Life Sciences Innovation Awards – SAN JOSE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and |
Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral ResearchSAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present an abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) taking place on October 13-16, 2023 in Vancouver, British Columbia, Canada. The details of the presentation are as follows: A |